Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
adalimumab (Humira®)
Reference No. 8
Publication date:
01/05/2012
Appraisal information
adalimumab (Humira®) 40 mg solution for injection
Company:
AbbVie Ltd
BNF category:
Musculoskeletal and joint diseases
NMG meeting date:
21/02/2012
AWMSG meeting date:
21/03/2012
Submission Type:
Limited Submission
Status:
Superseded
Advice No:
0812
Ratification by Welsh Government:
25/04/2012
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) in combination with methotrexate is recommended as an option for use within NHS Wales for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. Adalimumab (Humira®) can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. AWMSG is of the opinion that adalimumab (Humira®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
adalimumab (Humira) 8 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
adalimumab (Humira) 8 ASAR
Clinical Expert (CE) Summary
Download
adalimumab (Humira) 8 CE summary